The gene therapy player survived 2022 relatively unscathed, but big tests remain.
Evaluate Vantage's coverage of the Ash 2022 congress.
Meanwhile, there was bad blood between cell therapy players and their investors.
Sangamo emulates Editas, while Crispr/Vertex and Bluebird add weight to their ambitions.
The approval is good for CSL, and better for Uniqure.
Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.
But, with Applied Genetic Technologies Corporation, can lightning strike a third time?